Premium
Clinical Pharmacology of Topiramate: A Review
Author(s) -
Garnett William R.
Publication year - 2000
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1528-1157.2000.tb02174.x
Subject(s) - topiramate , medicine , clinical pharmacology , neuroscience , pharmacology , epilepsy , psychology , psychiatry
Summary: Clinical success with an antiepileptic drug (AED) depends primarily on its efficacy and tolerability. Clinicians also need to have a basic understanding of an AED's pharma‐cokinetic characteristics, particularly those affecting the potential for drug interactions such as hepatic enzyme inhibition or induction and protein‐binding displacement. Successful treatment may be complicated by pharmacokinetic characteristics such as a short half‐life, nonlinear kinetics, and active metabolites. Pharmacokinetic characteristics that make a drug easy to use may affect patient adherence. In general, newer AEDs such as topiramate (TPM) are simpler to use than traditional AEDs because they have more favorable pharmacokinetic characteristics and fewer drug interactions.